IGC IGC PHARMA INC revenue, earnings and financials

For the quarter ended June 30, 2026, IGC PHARMA INC reported revenue of $265K (down 19.2% from a year earlier), net income of −$2.94M and diluted EPS of −$0.03; for the fiscal year ended March 2025 revenue was $1.27M, down 5.5% on the year before.

IGC annual revenue and earnings

• Fiscal year ended Mar 2025: revenue $1.27M, gross profit $619K, operating income −$7.45M, net income −$7.12M (margin -560.3%), EPS −$0.09
• Fiscal year ended Mar 2024: revenue $1.35M, gross profit $733K, operating income −$9.80M, net income −$13.0M (margin -966.5%), EPS −$0.22
• Fiscal year ended Mar 2023: revenue $911K, gross profit $442K, operating income −$11.6M, net income −$11.5M (margin -1263.0%), EPS n/a
• Fiscal year ended Mar 2022: revenue $397K, gross profit $194K, operating income −$15.4M, net income −$15.0M (margin -3782.4%), EPS n/a

IGC quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $265K (down 19.2% year over year), net income −$2.94M, EPS −$0.03
• Quarter ended Mar 31, 2026: revenue $317K (down 3.9% year over year), net income −$2.40M, EPS −$0.02
• Quarter ended Sep 30, 2025: revenue $191K (down 53.6% year over year), net income −$1.82M, EPS −$0.02
• Quarter ended Jun 30, 2025: revenue $328K (up 20.6% year over year), net income −$1.60M, EPS −$0.02
• Quarter ended Mar 31, 2025: revenue $330K (up 11.9% year over year), net income −$1.20M, EPS −$0.02
• Quarter ended Dec 31, 2024: revenue $257K (up 26.0% year over year), net income −$1.83M, EPS −$0.02
• Quarter ended Sep 30, 2024: revenue $412K (up 41.6% year over year), net income −$1.72M, EPS −$0.02
• Quarter ended Jun 30, 2024: revenue $272K (down 51.0% year over year), net income −$2.38M, EPS −$0.03
• Quarter ended Mar 31, 2024 (from the annual report): revenue $295K (up 78.8% year over year), net income −$2.89M, EPS n/a
• Quarter ended Dec 31, 2023: revenue $204K (down 38.6% year over year), net income −$5.59M, EPS −$0.09
• Quarter ended Sep 30, 2023: revenue $291K (up 44.1% year over year), net income −$2.45M, EPS −$0.05
• Quarter ended Jun 30, 2023: revenue $555K (up 161.8% year over year), net income −$2.08M, EPS n/a
• Quarter ended Mar 31, 2023 (from the annual report): revenue $165K (up 35.2% year over year), net income −$4.03M, EPS n/a
• Quarter ended Dec 31, 2022: revenue $332K (up 133.8% year over year), net income −$2.25M, EPS n/a
• Quarter ended Sep 30, 2022: revenue $202K (up 260.7% year over year), net income −$2.44M, EPS n/a
• Quarter ended Jun 30, 2022: revenue $212K (up 175.3% year over year), net income −$2.79M, EPS n/a
• Quarter ended Mar 31, 2022 (from the annual report): revenue $122K, net income −$6.50M, EPS n/a
• Quarter ended Dec 31, 2021: revenue $142K, net income −$2.38M, EPS −$0.05
• Quarter ended Sep 30, 2021: revenue $56.0K, net income −$4.34M, EPS −$0.09
• Quarter ended Jun 30, 2021: revenue $77.0K, net income −$1.79M, EPS −$0.04

IGC cash flow, buybacks and dividends

• Fiscal year ended Mar 2025: operating cash flow −$4.80M, share buybacks n/a
• Fiscal year ended Mar 2024: operating cash flow −$5.20M, share buybacks n/a
• Fiscal year ended Mar 2023: operating cash flow −$7.05M, share buybacks n/a
• Fiscal year ended Mar 2022: operating cash flow −$7.46M, share buybacks n/a

IGC balance sheet

• Jun 30, 2026: cash $331K, total assets $9.50M, total liabilities $3.36M, shareholders' equity $6.13M
• Mar 31, 2026: cash $207K, total assets $9.19M, total liabilities $3.06M, shareholders' equity $6.12M
• Dec 31, 2025: cash $900K, total assets $9.71M, total liabilities $2.29M, shareholders' equity $7.42M, long-term debt $131K
• Sep 30, 2025: cash $1.11M, total assets $9.74M, total liabilities $1.65M, shareholders' equity $8.09M, long-term debt $132K
• Jun 30, 2025: cash $454K, total assets $7.94M, total liabilities $1.87M, shareholders' equity $6.08M, long-term debt $133K
• Mar 31, 2025: cash $405K, total assets $8.75M, total liabilities $2.42M, shareholders' equity $6.33M, long-term debt $134K
• Dec 31, 2024: cash $470K, total assets $9.08M, total liabilities $2.82M, shareholders' equity $6.26M, long-term debt $134K
• Sep 30, 2024: cash $1.55M, total assets $10.4M, total liabilities $2.99M, shareholders' equity $7.38M, long-term debt $135K

What is IGC's revenue?

IGC PHARMA INC reported $1.27M of revenue for the fiscal year ended March 2025.

Is IGC profitable?

No. IGC PHARMA INC lost $7.12M in its latest fiscal year.

IGC ownership and insider trades · All stocks